Redx Pharma plc Redx to present at AACR (7835T)
March 29 2021 - 4:00AM
UK Regulatory
TIDMREDX
RNS Number : 7835T
Redx Pharma plc
29 March 2021
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma to present at the American Association for Cancer
Research Annual Meeting
Alderley Park, 29 March 2021 Redx Pharma (AIM:REDX), the drug
discovery and development Company focused on oncology and fibrosis,
today announces that it will present a poster entitled 'Mechanism
of action of RXC004, a Wnt pathway inhibitor, in
genetically-defined models of cancer' at the American Association
for Cancer Research (AACR) Annual Meeting, being held virtually on
10 April 2021.
The poster relates to the Company's lead oncology candidate,
RXC004, a selective, orally bioavailable porcupine inhibitor
targeting the Wnt signalling pathway. The poster will present
preclinical data on the potential for the direct tumour-targeting
effects of RXC004 in genetically defined models of cancer.
Poster presentation:
Title: Mechanism of action of RXC004, a Wnt pathway inhibitor,
in genetically-defined models of cancer
Abstract: #998
Session name and category: Session PO.ET02.02 - Cellular
Responses to Anticancer Drugs
The abstract is available via the AACR annual meeting website,
here:
https://www.abstractsonline.com/pp8/#!/9325/presentation/2070
Copies of the poster will be available on the scientific
publication page of Redx's website following the conference at
https://www.redxpharma.com/scientific-publications/.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Chairman
Lisa Anson, Chief Executive
James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/Adam Dawes
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/Chris Lee/David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 20 7886
2500
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About RXC004
RXC004 is a potent, selective, oral small molecule inhibitor of
the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt
signalling pathway. Aberrant Wnt signalling contributes directly to
tumour growth and plays an important role in immune resistance to
treatment with immuno-oncology agents such as anti-PD-1 checkpoint
inhibitors.
By selecting patients with tumours that have high Wnt ligand
dependency, such as tumours with mutations in the RNF43 gene and
fusions in the RSPO gene family, RXC004 has an opportunity to
directly target tumour in addition to having an immune-enhancing
effect.
RXC004 is currently in a phase 1 study, with top line data
expected in H1 2021. Clinical proof-of-concept studies in
genetically-selected patients with metastatic colorectal cancer
(monotherapy and immuno-oncology combination), genetically selected
pancreatic cancer and all comers biliary cancer are expected to
initiate following completion of phase 1.
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic disease, aiming to progress them to clinical proof of
concept. Redx's lead oncology asset, RXC004, is currently in a
phase 1 study in patients with advanced malignancies with top line
data expected in H1 2021 and the Company's selective ROCK2
inhibitor, RXC007, is expected to enter a phase 1 clinical study in
H1 2021.
The Company's core capability of converting medicinal chemistry
insights into differentiated and commercially attractive small
molecule drug candidates against clinically validated targets has
been recognized by others. Over the last three years the company
has completed four major preclinical stage deals with AstraZeneca,
Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUGAWUPGUMB
(END) Dow Jones Newswires
March 29, 2021 04:00 ET (08:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024